Google Next Investors “Licence to Kill” It’s free to sign up....

Google Next Investors “Licence to Kill”

It’s free to sign up. Very good write up on ALA.  What’s interesting is the content related to CarT therapies and to IMU’ s agreement with ALA.


“Given historical difficulties encountered in treating solid tumours - ALA’s strategy of licensing from the best seems a sound one here.

It’s another string to the bow for ALA - as the company builds out an expanding arsenal of cancer fighting technologies.

Here’s our quick takeaways from today’s ALA announcement

• The data is positive and justifies ALA’s move to exclusively licence it - mice that had a solid tumour and were treated using this tech survived in much greater numbers over a 60 day period.

• The tech comes from a highly esteemed research program - the tech comes from one of the foremost experts in the specialised field that ALA works in.

• The terms of the deal won’t incur any upfront costs to ALA - we think this is another well worked commercial agreement that won’t impact ALA’s cash burn as it approaches a Phase 1 clinical trial this year for blood cancer.

• It de-risks ALA’s preclinical work on solid tumours - animal studies (mice) are usually the precursor to a move into human trials in a Phase 1 study. So this potentially clears a hurdle for the solid tumour side of ALA’s research.

• Potential benefits for Solid Tumour Therapy (partnership with Imugene) - this is important. Today’s announcement indicated that the armouring technology may be able to be combined with the Solid Tumour Therapy that ALA is developing with the $716M capped Imugene.”